



an Open Access Journal by MDPI

Cannabinoids as Medicines

Guest Editor:

Prof. Dr. Gary J. Stephens

School of Pharmacy, University of
Reading, Whiteknights, PO Box
228, Reading RG6 6AJ, UK

Deadline for manuscript
submissions:

closed (30 November 2018)

Message from the Guest Editor

The last three decades have seen real advances in the characterization of the body's endocannabinoid system, with detailed knowledge of cannabinoid receptor subtypes, endocannabinoid metabolic pathways and their cell signaling pathways. In parallel, advocacy, and some sanction, of the use of medicinal marijuana, often based on anecdotal evidence, has become a pertinent topic of societal and scientific debate. At a scientific level, interest has tended to shift away from use of Δ^9 -tetrahydrocannabinol (THC), due to its psychoactive intoxicant effects, towards alternative plant-derived phytocannabinoids or synthetic cannabinoids and their potential therapeutic applications. Despite some high-profile clinical failures, recent well-controlled clinical trials have begun to advance non-THC cannabinoids towards human therapeutic use. Authors are invited to submit original and review articles of basic science, preclinical and clinical findings contributing to the understanding of the current state of play and future potential for cannabinoids as medicines to be published in this Special Issue of *Pharmaceuticals*.



mdpi.com/si/11086

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com